|
Study of cabozantinib in second line under real-life setting in patients with advanced renal cell carcinoma (aRCC): Study design of a French retrospective, multicenter study (OCTOPUS). |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; MSD; Novartis; Pfizer; Roche; Sanofi |
Research Funding - Bayer (Inst); Ipsen (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; MSD; Pfizer; Roche |
|
|
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; Pfizer; Sanofi |
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; BMS; Ipsen; janssen; Pfizer; Sanofi |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; Intuitive Surgical; MSD |
Consulting or Advisory Role - Ipsen; MSD |
Research Funding - ConMed; Intuitive Surgical |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Pfizer |
|
|
|
Stock and Other Ownership Interests - Ipsen |
|
|
|
Stock and Other Ownership Interests - Ipsen |
|
|
Consulting or Advisory Role - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); Janssen (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - BMS; Ipsen; MSD |